FGP
SRPT icon

Freestone Grove Partners’s Sarepta Therapeutics SRPT Stock Holding History

Freestone Grove Partners’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$151K Buy
+6,920
New +$134K ﹤0.01% 765
2025
Q4 		– Sell
-18,515
Closed -$357K – 932
2025
Q3 		$357K Buy
+18,515
New +$330K ﹤0.01% 588

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Freestone Grove Partners's SRPT Position: Q1 2026 in Review

Freestone Grove Partners opened a new position in Sarepta Therapeutics (SRPT) in Q1 2026: 6,920 shares worth $151K. The stake represents ﹤0.01% of the portfolio and ranks #765 among its holdings. This is a return to the name: Freestone Grove Partners previously reported a position in SRPT as recently as Q3 2025.

Freestone Grove Partners first reported a position in SRPT in Q3 2025 and has held it in 2 quarters since. The position peaked at $357K in Q3 2025. 339 funds tracked by Wall St. Rank hold SRPT as of Q1 2026.

  • Freestone Grove Partners held 6,920 shares of Sarepta Therapeutics worth $151K as of Q1 2026.
  • Sarepta Therapeutics was a new Freestone Grove Partners position in Q1 2026.
  • Sarepta Therapeutics made up ﹤0.01% of Freestone Grove Partners's portfolio in Q1 2026, its #765 holding.
  • Freestone Grove Partners first reported a position in Sarepta Therapeutics in Q3 2025 and has held it in 2 quarters since.
  • Freestone Grove Partners's Sarepta Therapeutics position peaked at $357K in Q3 2025.
  • 339 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2026.

Based on Freestone Grove Partners's 13F filing for Q1 2026, filed 15 May 2026.